Literature DB >> 19523041

Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice.

Emilie Belkaï1, Jean-Michel Scherrmann, Florence Noble, Cynthia Marie-Claire.   

Abstract

The delta opioid system is involved in the behavioral effects of various drugs of abuse. However, only a few studies have focused on the possible interactions between the opioid system and the effects of 3,4-methylenedioxymethamphetamine (MDMA). In order to examine the possible role of the delta opioid system in MDMA-induced behaviors in mice, locomotor activity and conditioned place preference (CPP) were investigated in the presence of naltrindole (NTI), a selective delta opioid antagonist. Moreover, the consequences of acute and chronic MDMA administration on pro-enkephalin (Penk) and pro-opiomelanocortin (Pomc) gene expression were assessed by real-time quantitative polymerase chain reaction (QPCR). The results showed that, after acute MDMA administration (9 mg/kg; i.p.), NTI (5 mg/kg, s.c.) was able to totally block MDMA-induced hyperlocomotion. Penk gene expression was not modulated by acute MDMA, but a decrease of Pomc gene expression was observed, which was not antagonized by NTI. Administration of the antagonist prevented the acquisition of MDMA-induced CPP, suggesting an implication of the delta opioid receptors in this behavior. Following chronic MDMA treatment, only the level of Pomc was modulated. The observed increase was totally blocked by NTI pre-treatment. All these results confirm the interactions between the delta opioid system (receptors and peptides) and the effects of MDMA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523041      PMCID: PMC2922624          DOI: 10.1111/j.1369-1600.2009.00156.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  42 in total

Review 1.  Ecstasy: pharmacology and neurotoxicity.

Authors:  Jenny Morton
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

2.  Opioidergic modulation of cocaine conditioned place preferences.

Authors:  E J Bilsky; M J Montegut; C L Delong; L D Reid
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate.

Authors:  B Gough; S F Ali; W Slikker; R R Holson
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

4.  MDMA produces stimulant-like conditioned locomotor activity.

Authors:  L H Gold; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature.

Authors:  Esther O'Shea; Laura Orio; Isabel Escobedo; Veronica Sanchez; Jorge Camarero; Alfred Richard Green; Maria Isabel Colado
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

6.  Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study.

Authors:  A Zangen; R Nakash; G Yadid
Journal:  J Neurochem       Date:  1999-12       Impact factor: 5.372

Review 7.  Multiple molecular and neuropharmacological effects of MDMA (Ecstasy).

Authors:  Rabi Simantov
Journal:  Life Sci       Date:  2004-01-02       Impact factor: 5.037

8.  The role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice.

Authors:  Paul Marquez; Ramkumarie Baliram; Ibrahim Dabaja; Nagaraju Gajawada; Kabirullah Lutfy
Journal:  Psychopharmacology (Berl)       Date:  2008-01-06       Impact factor: 4.530

9.  Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice.

Authors:  Nadia Benturquia; Cindie Courtin; Florence Noble; Cynthia Marie-Claire
Journal:  Brain Res       Date:  2008-03-20       Impact factor: 3.252

10.  Rewarding properties of beta-endorphin as measured by conditioned place preference.

Authors:  M Amalric; E J Cline; J L Martinez; F E Bloom; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more
  4 in total

Review 1.  The delta opioid receptor: an evolving target for the treatment of brain disorders.

Authors:  Amynah A Pradhan; Katia Befort; Chihiro Nozaki; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  Trends Pharmacol Sci       Date:  2011-09-17       Impact factor: 14.819

Review 2.  Delta opioid receptors in brain function and diseases.

Authors:  Paul Chu Sin Chung; Brigitte L Kieffer
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

3.  Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties.

Authors:  Marianne Seleman; Hélène Chapy; Salvatore Cisternino; Cindie Courtin; Maria Smirnova; Joël Schlatter; Fouad Chiadmi; Jean-Michel Scherrmann; Florence Noble; Cynthia Marie-Claire
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

4.  Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.

Authors:  Anika Mann; Sophia Liebetrau; Marie Klima; Pooja Dasgupta; Dominique Massotte; Stefan Schulz
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.